Published • loading... • Updated
Pfizer CFO to depart; GSK wins approval for UTI drug
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Pfizer CFO to depart; GSK wins approval for UTI drug
Pfizer CFO exits; GSK wins FDA nod for oral UTI drug; Apellis trial paused; plus Mersana ADC dropped, TORL ADC data, Corcept resubmission, Verastem pancreatic update, Legend offering, COUR Series B and two program cuts, cAMPfield $180M debut and LabGenius-LG Chem AI pact.
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
